Université de Sherbrooke

usherbrooke.ca

Live pipeline data from ClinicalTrials.gov, refreshed daily.

Total trials

294

Active

67

Phase 3

15

Total enrollment

59,437

Pipeline matrix

Showing 18 of 18 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
1- Vasopressor - Mean arterial pressure 56-601
2- Vasopressor - Mean arterial pressure 61-651
3- Vasopressor - Mean arterial pressure 66-701
4- Vasopressor - Mean arterial pressure 71-751
Androgen blockade + radiation therapy1
Dupilumab Prefilled Syringe1
CBD Oral Solution2
Tacrolimus1
IA Carboplatin + IA Caelyx1
IA Carboplatin + IA Etoposide Phosphate1
IA Carbo+ Radiation1
Celecoxib1
Nicotinic acid2
Topical Capsaicin Cream1
Fluconazole 150 mg1
Heparin1
Niacin1
Antipsychotic drugs1

Next readouts

  • 2025-12
  • 2025-12-10
  • 2026-11-01
  • 2026-11-30
  • 2026-12-15
  • 2026-12-30
  • 2026-12-31
  • 2027-04
  • 2027-12-01
  • 2027-12-15

Top conditions

  • Healthy14
  • Chronic Pain13
  • Obesity12
  • Type 2 Diabetes9
  • Stroke7
  • Gestational Diabetes Mellitus6
  • Asthma5
  • Urinary Incontinence4

Frequently asked questions about Université de Sherbrooke

How many clinical trials does Université de Sherbrooke have on ClinicalTrials.gov?
Université de Sherbrooke is listed as the lead sponsor on 294 clinical trials in ClinicalTrials.gov, 67 of which are currently active (recruiting, enrolling, or ongoing).
How many of Université de Sherbrooke's trials are in Phase 3?
15 of Université de Sherbrooke's trials are in Phase 3, spread across 18 active drug programs.
What therapeutic areas does Université de Sherbrooke focus on?
Université de Sherbrooke's most-studied conditions on ClinicalTrials.gov are Healthy, Chronic Pain, Obesity, Type 2 Diabetes, Stroke.
When are Université de Sherbrooke's next clinical trial readouts?
Université de Sherbrooke has 10 upcoming primary-completion readouts tracked here; the soonest is “Calcineurin Inhibitor in NEuRoloGically Deceased Donors to Decrease Kidney delaYed Graft Function (CINERGY)”, expected around 2025-12.